AXLA | Axcella Health Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3600 - 4.58
52 Week Range	0.3600 - 4.58
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	6,782
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	337,493,596
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-05-09

Valuation
Profitability
Growth
Health
P/E Ratio	-0.25
Forward P/E Ratio	N/A
EPS	-18.25
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	11
Country	USA
Website	AXLA

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

AXLA's peers: ADIL, AKTX, ARTL, CYCN, MBIO, NNVC, PTN, RNXT, SLRX, VYNE

*Chart delayed

Analyzing fundamentals for AXLA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see AXLA Fundamentals page.

Watching at AXLA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on AXLA Technicals page.